Bombardier and Hitachi partner on joint bid for £2.75bn HS2 contract

By Sophie Chapman
Share
The Canadian transport manufacturer, Bombardier, has submitted a joint bid with the Japanese conglomerate, Hitachi, to build trains for the UK’s High...

The Canadian transport manufacturer, Bombardier, has submitted a joint bid with the Japanese conglomerate, Hitachi, to build trains for the UK’s High Speed Two (HS2) project.

The £2.75bn (US$3.63) will see the winning bid design, build, and maintain a minimum of 54 high-speed trains for Phase 1, Sky News reported.

So far, the HS2 has received five bids for the contract – Alstom Transport, Bombardier and Hitachi, Construcciones y Auxiliar de Ferrocarriles (CAF), Patentes Talgo, and Siemens. The winning bid will be announced by HS2 by the end of 2019.

“HS2 will form the backbone of Britain’s future rail network and is a major investment in our future prosperity,” stated Karen Boswell, Hitachi Rail’s Managing Director.

SEE ALSO:

“By joining together in partnership with Bombardier, we will draw on a huge wealth of UK experience and the best in modern technology – including our pioneering ‘bullet train’ experience.”

“Our aim is to deliver a new British icon that will be recognised around the world - a Spitfire for the British railway,” she added, according to Sky News.

“We will combine both companies' global high-speed expertise with unrivalled British experience, and help generate skills and prosperity across a number of UK regions,” noted Richard Hunter, UK Managing Director of Bombardier, claims Sky News.

Share

Featured Articles

Axiado & Pegatron Partner to Boost Server Security

Axiado and Pegatron's collaboration enhances server security for manufacturing, delivering robust AI-driven protection for modern industrial data centres

Genus Power Showcases Smart Metering Innovation & Diversity

Genus Power impresses US delegation with cutting-edge smart metering technology and a diverse workforce, advancing global clean energy solutions

Telix's bid to Expand Access to Cancer Radiopharmaceuticals

Rhine Pharma, spun off by Telix, aims to open production to improve worldwide access to radiopharmaceuticals for cancer imaging & treatment

UK Automotive Manufacturers Face Net Zero Challenge

Sustainability & ESG

Samsung Biologics Secures US$1.24Bn Manufacturing Deal

Production & Operations

How is ABB Revolutionising Automotive Sustainability?

Sustainability & ESG